Table 1.
Patient characteristics (n = 46)
| Variables | n (%) or median (range) | |
|---|---|---|
| Male: Female | 28 (61%)/18 (39%) | |
| Age, years | 68.5 (39-84) | |
| ECOG-PS | 0 | 39 (85%) |
| 1 | 7 (15%) | |
| Primary disease | Extrahepatic | 19 (41%) |
| Intrahepatic | 8 (17%) | |
| Gallbladder | 10 (22%) | |
| Ampulla of Vater | 9 (20%) | |
| Pathologically stage (UICC) | I | 10 (22%) |
| II | 29 (63%) | |
| III | 7 (15%) | |
| Surgical procedure | Pancreatoduodenectomy | 25 (54%) |
| Hepatectomy (without bile duct resection) | 6 (13%) | |
| Hepatectomy (with bile duct resection) | 6 (13%) | |
| Extended cholecystectomy | 9 (20%) | |
| Morbidity (Clavien-Dindo ≥3) | Total | 10 (22%) |
| Pancreatic fistula | 8 (17%) | |
| Liver abcess | 1 (2%) | |
| Intraabdominal abcess | 1 (2%) | |
| Residual tumor | 0 | 43 (94%) |
| 1 | 3 (7%) | |
| Lymph node metastasis | Positive | 20 (46%) |
| CEA, ng/dL | 1.8 (0.1-54.0) | |
| CA19–9, ng/dL | 17.0 (1.0-3197) |
Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9